In this study, we investigated the biochemical mechanisms of agonist action at the G protein-coupled D 2 S]GTP␥S binding remains the slowest step, whereas for partial agonists, another (GDP-independent) step, probably ternary complex breakdown, becomes rate-determining.
There is much interest in understanding the mechanisms of action of agonists at receptors (agonist efficacy) and the mechanistic distinction between full and partial agonists ( (Black and Leff, 1983; Clarke and Bond, 1998; Colquhoun, 1998; Strange, 1999; Kenakin, 2002) . For the G proteincoupled receptors (GPCRs), an influential biochemical model of GPCR action has been the ternary complex model and its recent extensions (De Lean et al., 1980; Samama et al., 1993; Weiss et al., 1996) . The model describes a ground state of the receptor (R) which can isomerize to a partially activated form (R*) which is able to couple better to the G protein to form the active (R*G) state.
The ternary complex model accounts for differences in the relative efficacy of full and partial agonists in terms of different extents of stabilization of active (AR*G) and inactive (AR) states of the receptor. Full agonists stabilize R*G better than partial agonists so that relative efficacy is explained in terms of the differential stabilization of a single activated state. G protein activation and GDP/GTP exchange follow accordingly.
This model has been examined using ligand-binding studies to determine affinities of agonists for G protein-coupled (higher affinity, K h ) and -uncoupled (lower affinity, K l ) forms of the receptor. Some studies report a correlation between the K l /K h ratio for agonists and their relative efficacy (De Lean et al., 1980; Kearn et al., 1999; Egan et al., 2000; Watson et al., 2000; Payne et al., 2002; Alder et al., 2003) , whereas other studies do not (Gardner et al., 1997; Gardner and Strange, 1998; Payne et al., 2002) . It seems that there may be additional factors influencing relative efficacy such as differential abilities of some agonists to induce G protein activation within AR*G. Different agonists may stabilize different activated states of receptors leading to differential activities (Seifert et al., 2001; Waelbroeck, 2001) . G protein activation occurs, however, as part of a cycle of reactions ( Fig. 1) (Waelbroeck, 2001; Mosser et al., 2002; Zhong et al., 2003) , and the overall rate of G protein activation may be dependent on several of the component processes, although the slowest of these will limit the overall rate. The reactions of the cycle are as follows: 1) agonist (A) binds to receptor to stabilize AR*; 2) AR* and G GDP combine to form AR*G: for some agonists AR*G stability is a guide to agonist relative efficacy; some agonists can produce a stable AR*G complex but are partial agonists (Gardner et al., 1997; Gardner and Strange, 1998; Payne et al., 2002) and so their activity must be limited by another event; 3) GDP release: this is typically considered to be the rate-determining step in GPCR activation in the absence of agonist (Ross, 1989) . In the presence of agonist, GDP dissociation is accelerated, and GDP association decreased (Florio and Sternweis, 1989) . GDP release could, however, be the slowest step in the cycle for some agonists, despite strong stabilization of AR*G; 4) GTP binding: cells contain high concentrations of GTP (ϳ50 M) (Otero, 1990; Jinnah et al., 1993) so that this step will be fast, and another step is rate-determining. This step may be examined using the GTP analog ([ 35 S]GTP␥S). In general, these assays are performed at low concentrations of [ 35 S]GTP␥S, and this step may become rate-determining (Waelbroeck, 2001) ; 5) AR*G dissociates, releasing AR, G ␣ GTP, and G ␤␥ : this step may be agonist-dependent for some receptors (Hausdorff et al., 1990; Van Koppen et al., 1994) and could be rate-determining if an agonist were unable to mediate rapid breakdown of AR*G; and 6) the intrinsic GTPase of the G protein hydrolyzes GTP to GDP and deactivates G ␣ : this step itself is independent of agonist because it is an intrinsic activity of the G protein but is unlikely to be rate-determining because, in the presence of proteins with GTPase-accelerating activity, this step is fast (Ross and Wilkie, 2000) .
There are, therefore, several steps in the cycle that are regulated by agonists and that could determine the relative efficacy of agonists. It is not known whether the rate-determining step in the cycle is the same for all agonists. In this study, therefore, we examined the ability of a range of full and partial agonists to mediate G protein activation via the D 2 dopamine receptor. We have perturbed the function of the G protein cycle by altering the concentrations of both GDP and GTP␥S to understand which step in the cycle is ratelimiting for different agonists.
Materials and Methods

Materials. [
35 S]GTP␥S (ϳ37 TBq/mmol) and [ 3 H]spiperone (ϳ600 GBq/mmol) were purchased from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK). Optiphase HiSafe-3 scintillation fluid was purchased from PerkinElmer Life and Analytical Sciences (Cambridge, UK). Dopamine, bromocriptine, and (Ϯ)-7-OH-DPAT were purchased from Tocris Cookson Inc. (Bristol, UK). NPA, ␤-phenylethylamine, m-tyramine, and p-tyramine were purchased from Sigma Chemical (Poole, Dorset, UK).
Cell Culture. CHO cells stably expressing native D 2short dopamine receptors (Wilson et al., 2001) were grown in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum and 400 g/ml active geneticin (to maintain selection pressure). Cells were grown at 37°C in a humidified atmosphere of 5% CO 2 .
Membrane Preparation. Membranes were prepared from CHO cells expressing D 2short dopamine receptors as described previously (Castro and Strange, 1993) . In brief, confluent 175-cm 2 flasks of cells were washed once with 5 ml HEPES buffer (20 mM HEPES, 1 mM EGTA, 1 mM EDTA, and 10 mM MgCl 2 , pH 7.4). Cells were then removed from the surface of the flasks using 5 ml of HEPES buffer and glass balls (2 mm in diameter) and were then homogenized using an Ultra-Turrax homogenizer (two 5-s treatments). The homogenate was centrifuged at 1700g (for 10 min at 4°C), after which the supernatant was centrifuged at 48,000g (for 60 min at 4°C). The resulting pellet was resuspended in HEPES buffer at a concentration of 3 to 5 mg of protein/ml as determined by the method of Lowry et al. (1951) and stored in aliquots at Ϫ70°C until use.
Radioligand Binding Experiments. Cell membranes (25 g) were incubated with [ 3 H]spiperone (0.35 nM) and competing drugs in HEPES buffer (20 mM HEPES, 1 mM EGTA, 1 mM EDTA, 10 mM MgCl 2 , and 100 mM NaCl, pH 7.4, using KOH, containing 0.1 mM dithiothreitol) in a final volume of 1 ml for 3 h at 25°C. The assay was terminated by rapid filtration (through Whatman GF/C filters) using a Brandel cell harvester (Brandel Inc., Gaithersburg, MD) followed by four washes with 4 ml of ice-cold phosphate-buffered saline (0.14 M NaCl, 3 mM KCl, 1.5 mM KH 2 PO 4 , and 5 mM Na 2 HPO 4 , pH 7.4) to remove unbound radioactivity. Filters were soaked in 2 ml of scintillation fluid for at least 5 h, and bound radioactivity was determined by liquid scintillation counting. 35 S]GTP␥S with 9.5 nM GTP␥S) for 3 min in HEPES buffer at 30°C containing 0.1 mM dithiothreitol. In the absence of GDP, incubation times with 0.1 nM [
35 S]GTP␥S were reduced to 15 min. The assay was terminated by rapid filtration (through Whatman GF/C filters) using a Brandel cell harvester followed by four washes with 4 ml of ice-cold phosphate-buffered saline (0.14 M NaCl, 3 mM KCl, 1.5 mM KH 2 PO 4 , and 5 mM Na 2 HPO 4 , pH 7.4) to remove unbound radioactivity. Filters were soaked in 2 ml of Optiphase HiSafe-3 for at least 5 h, and bound radioactivity was determined by liquid scintillation counting.
Data Analysis. Radioligand binding and [ 35 S]GTP␥S binding data were analyzed by nonlinear regression using Prism (GraphPad Software Inc., San Diego, CA). Statistical significance over multiple data sets was determined using an unpaired two-way analysis of variance followed by a Bonferroni post-test, whereas that for two groups was determined using a t test. Statistical significance was determined as P Ͻ 0.05.
Results
Effects of Different Concentrations of GDP and [ 35 S]GTP␥S on Agonist Stimulation of [ 35 S]GTP␥S Binding
Maximal Agonist-Stimulated Effect and Relative Agonist Efficacy. The maximal agonist-stimulated effect and relative agonist efficacy were determined from the stimulation of [
35 S]GTP␥S binding by agonists in membranes of CHO cells expressing the D 2 receptor (Wilson et al., 2001) (expression level of D 2 receptor, 1-1.5 pmol/mg of protein). Agonist-stimulated [
35 S]GTP␥S binding is caused by the D 2 receptor because there is no stimulation in untransfected cells (Gardner et al., 1996) . The agonist-stimulated response is completely inhibited after pertussis toxin treatment (100 ng/ml for 18 h; data not shown), indicating a role for G i/o (Raymond et al., 1993; Gettys et al., 1994) .
The stimulation of [ 35 S]GTP␥S binding by two full agonists (dopamine and NPA) and two partial agonists (p-tyramine and (Ϯ)-7-OH-DPAT) was assessed in the presence of increasing concentrations of GDP (0.3-30 M) and using two concentrations of [
35 S]GTP␥S (0.1 and 10 nM). The four agonists were used at maximally stimulating concentrations, and total [
35 S]GTP␥S binding was corrected for the agonistindependent binding to give the agonist-stimulated binding (Fig. 2) . The association rate of [
35 S]GTP␥S binding stimulated by dopamine was much faster at the higher [
35 S]GTP␥S concentration (10 nM) (t 1/2 , 1-2 min; data not shown) compared with the rate at the lower concentration of [
35 S]GTP␥S (0.1 nM) (t 1/2 , 10-15 min) (Gardner et al., 1996) (Fig. 2, B and D) . When relative agonist efficacies were compared at the two concentrations of [ 35 S]GTP␥S, it was seen that the relative efficacy of the partial agonists was lower at the higher [
35 S]GTP␥S concentration (Fig. 2, B and D) .
Given that the relative efficacy of partial agonists was higher at the lower GDP concentrations, we performed some assays in the absence of GDP. Under these conditions, both full and partial agonists were still able to promote [ 35 S]GTP␥S binding over basal levels (Table 1 Table 2 ). In contrast, bromocriptine, which (Gardner et al., 1997) , shows no change in EC 50 value with changing GDP concentration. With the exclusion of bromocriptine, when the pEC 50 was plotted against log[GDP], there was no significant difference between the slopes of the lines (P Ͼ 0.05), and a mean slope of Ϫ0.31 was obtained.
When the [ 35 S]GTP␥S concentration was increased to 10 nM, the EC 50 value for the two full agonists tested was shifted rightward as before as the GDP concentration was increased, whereas for the two partial agonists, the EC 50 value was much less affected by GDP. This effect is emphasized in the pEC 50 versus log[GDP] plots (Fig. 5) . Linear relationships between pEC 50 and log[GDP] were still observed, but there were significantly greater slopes for the full agonists, NPA and dopamine, compared with the partial agonists (Ϯ)-7-OH-DPAT and p-tyramine (P Ͻ 0.05) (Fig. 5 and Table 3 ).
Binding of Full and Partial Agonists to D 2 Dopamine Receptors. The binding of the agonists (dopamine, NPA, p-tyramine, and (Ϯ)-7-OH-DPAT) was determined in competition versus the binding of [ 3 H]spiperone using assay buffer containing 100 mM NaCl as in the [
35 S]GTP␥S binding experiments (see above). In each case, the competition data were fitted best by a two-binding site model, and the derived dissociation constants (K h , K l ) are given in Table 2 .
Discussion
In this study, we have examined some basic mechanisms of agonist action using the D 2 dopamine receptor as a model GPCR, with the aim of understanding the mechanistic distinction between full and partial agonists. For the GPCRs, differences in the relative efficacy of agonists have been explained using the ternary complex model (De Lean et al., 1982; Lefkowitz et al., 1993; Weiss et al., 1996) , whereby partial agonists stabilize the ternary complex (AR*G) less well than full agonists. The model does not always account for relative efficacy, and this may relate to the fact that GPCR activation depends on a cycle of reactions (Fig. 1 ) (Waelbroeck, 2001; Mosser et al., 2002; Zhong et al., 2003) . During receptor activation, the reactions of the cycle will not be at equilibrium, and different agonists may influence steps in the cycle differentially. In this report, we examined how agonists with different relative efficacies influence the steps in the cycle using the D 2 dopamine receptor as a model system. From the data, we have shown that full and partial agonists differ in their abilities to modulate different reactions in the G protein cycle. The study therefore provides a mechanistic basis for the distinction between full and partial agonists.
We 1 nM) , the potency of each of the agonists tested, with the exception of bromocriptine, was reduced as the GDP concentration was increased. The effect of GDP was similar for each agonist, independent of its relative efficacy, as shown by the similar slopes of the lines relating pEC 50 and log [GDP] . The effects of GDP here reflect the binding of GDP to the AR*G state, leading to its breakdown and sequestration of G protein as G GDP . Higher concentrations of agonist are then required to stabilize AR*G in which [
35 S]GTP␥S binding occurs, and the EC 50 value for the agonist is increased. Simulations of these effects have been reported (McLoughlin and Strange, 2000) . The slope of the line relating pEC 50 and log[GDP] reflects the affinities of the agonist for the G protein-coupled and -uncoupled states of the receptor and the sensitivity of the agonist/receptor/G protein complex to GDP. Bromocriptine has been shown have similar affinities for the coupled and uncoupled states (Gardner et al., 1997) , so it is not surprising that it is insensitive to GDP.
When higher concentrations of [ 35 S]GTP␥S (10 nM) were used, the potencies of the two full agonists (NPA and dopamine) tested were sensitive to the effects of GDP. Indeed, the pEC 50 was more sensitive to log[GDP] than at the lower concentration of [
35 S]GTP␥S (P Ͻ 0.05). In contrast, the potencies of the two partial agonists [(Ϯ)-7-OH-DPAT and p-tyramine] were virtually independent of log[GDP] when 35 S]GTP␥S concentration and concomitant increase in overall rate may have led to a change in the rate-determining step for some agonists. For the partial agonists, at the higher concentration of [ 35 S]GTP␥S, another, GDP-independent, step may have become rate-determining. For this process to be GDP-independent, it must be subsequent to formation of AR*G, and a likely candidate could be ternary complex breakdown. For the full agonists, the rate-determining step at the higher concentration of 35 S]GTP␥S concentration, for the full agonists, the binding event is still the slowest process, whereas for the partial agonists, ternary complex breakdown may be the slowest process in the cycle. The 35 S]GTP␥S binding rate presumably reflect sequestration of G proteins reducing levels of AR*G and hence the overall rate of the cycle.
In addition to the effects of GDP on the maximal rates of [ 35 S]GTP␥S binding, there were effects on the relative efficacies of the partial agonists. The maximal rates of [ 35 S]GTP␥S binding of the partial agonists were more sensitive to GDP than those of the full agonists, resulting in a reduction in relative efficacy for the two partial agonists as GDP was increased. This suggests that differences in relative efficacy may reflect differences in GDP sensitivity of different agonist/receptor/G protein species; full agonists are able to overcome G protein sequestration more than partial agonists. For other GPCRs, it has been shown that agonists may affect the affinity of the receptor for the G protein (Tota and Schimerlik, 1990) . Thus, different AR*G complexes may seem differentially sensitive to GDP. The relative efficacies of the partial agonists were also generally lower at higher [ 35 S]GTP␥S concentrations, and this may reflect the change in the rate-determining step to ternary complex breakdown for which the partial agonists are deficient relative to the full agonists.
In the present study, bromocriptine stands out as having unusual properties in that its potency for stimulation of [ 35 S]GTP␥S binding, when measured at 100 pM [
35 S]GTP␥S, is insensitive to GDP, unlike the potencies of the other agonists tested (Fig. 5) . Bromocriptine exhibits similar behavior in ligand binding assays in that its binding is insensitive to guanine nucleotides unlike other agonists (Gardner et al., 1997; Gardner and Strange, 1998) . We have suggested that this reflects stabilization by bromocriptine, in the absence of G protein coupling, of a conformation of the receptor that is close to the conformation in the fully active G protein-coupled state (Strange, 1999 35 S]GTP␥S-binding event, to be rate-determining. For the partial agonists, however, another step, probably ternary complex breakdown, is slower and becomes rate-determining. These conclusions are of some significance in that the concentration of GTP in the cell is high (ϳ50 M) (Otero, 1990; Jinnah et al., 1993) , so that partial agonism in cells may be apparent because of this limitation of the rate of ternary complex breakdown.
Given that the experiments conducted here at the higher 35 S]GTP␥S. Concentration-response curves were constructed for dopamine (f), bromocriptine (Ⅺ), NPA (), (Ϯ)-7-OH-DPAT (ϫ), quinpirole (•), ␤-phenylethylamine (ࡗ), m-tyramine (OE), and p-tyramine (छ) at the indicated GDP concentrations, and the potency (EC 50 ) was determined as described in Fig. 4 and under Materials and Methods. Data shown are mean Ϯ S.E.M. of three to five experiments performed in triplicate. Statistical analysis is given in Table 3.   TABLE 2 The binding of agonists to D 2 dopamine receptors Agonist binding was determined in competition versus ͓ 3 H͔spiperone ‫3.0ف(‬ nM) in a buffer containing Na ϩ (100 mM) as described under Materials and Methods. Data were fitted best by a two-binding site model and analyzed by nonlinear regression to derive dissociation constants for the higher (K h ) and lower (K l ) affinity sites and the percentage of receptors in the high-affinity state (%R h (Payne et al., 2002) . The present set of data for the higher [
35 S]GTP␥S concentration is not extensive enough to allow this correlation to be examined, but this will be an important aim for future work in relating these in vitro assays to cellular assays.
